New Scripps Research trial will explore the effects of Lilly’s GLP-1 drug on reducing the symptoms of the debilitating disease.
El ensayo clínico, que busca reclutar a 1000 pacientes con COVID persistente en todo el país, explorará cómo la autoadministración de tirzepatida, el agonista del GLP-1 de Eli Lilly comercializado ...
Eli Lilly delivered a stunning financial performance that exceeded even the most optimistic market expectations, driven by unprecedented demand for its ...
Viking Therapeutics delivered a disappointing earnings report on October 22, revealing a quarterly loss of $0.81 per share that fell substantially short of ...
With a new generation of weight-loss drugs entering Indian markets, spelling hope for many, The Indian Express tracks the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback